Concluding her intervention in the ongoing meeting at Infarmed headquarters in Lisbon, Fátima Ventura has said contracts with suppliers “provide for the provision of vaccines adapted to Covid-19 variants”. Meantime the current vaccines are being evaluated ahead of green-lighting in Portugal: Novavax, Curevac, Sanofi, Sputnik V and Sinovac. Novavax and Sanofi are ‘protein based’; Curevac uses mRNA technology; Sputnik V is ‘viral vector’ and Sinovac uses an inactive virus.
